bxp2390
$IMNN The only financing path forward - outside of an outright sale, which is the second most sensible thing to pursue - is to give up global non-US rights to an international pharma for some amount that can fund another year or two of trials. It may seem like a steep price for complete rights if the trial succeeds, but desperate times call for desperate measures. I've spent a lot of time uploading papers and other information to some of the smarter AI tools and there is a small chance that the trial does succeed despite what all the bears note here because there is a differentiated mechanism here unlike prior IL-12 attemps at gene therapy.
11:17 AM
4
